Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases
We detail the absence of disease progression in a metastatic renal cell carcinoma case with multiple brain metastases more than 1 year after stereotactic radiation therapy followed by first-line pembrolizumab plus lenvatinib.
Authors
- Toshiharu Morikawa (ORCID: https://orcid.org/0009-0006-4430-0277)
- Taku Naiki (ORCID: https://orcid.org/0000-0002-7638-6048)
- Aya Naiki‐Ito (ORCID: https://orcid.org/0000-0003-0828-2033)
- Maria Aoki (ORCID: https://orcid.org/0000-0003-4120-204X)
- Nobuhiko Shimizu (ORCID: https://orcid.org/0000-0001-7280-2481)
- Masakazu Gonda (ORCID: https://orcid.org/0009-0002-9514-1561)
- Yukihiro Umemoto (ORCID: https://orcid.org/0000-0003-0692-2914)
- Takahiro Yasui (ORCID: https://orcid.org/0000-0003-2197-2477)
- Daisuke Matsumoto (ORCID: https://orcid.org/0000-0002-3429-6554)
- Shinji Kato
Institutions
- Nagoya City University (JP)
- Nagoya Medical Center (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2024-09-22
- DOI
- https://doi.org/10.1002/iju5.12786
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42